The positive readout in patients with non-relapsing secondary progressive multiple sclerosis comes on the heels of ...

The recent results of tolebrutinib in non-active secondary progressive MS presented at the ECTRIMS 2024 conference, reinforce the scientific hypothesis that targeting microglia in nSPMS is a valid ...

A study presented at ECTRIMS 2024 has identified critical biomarkers that can predict disability worsening in multiple ...

Key biomarkers identified can now predict disability progression in multiple sclerosis, offering potential for more ...

The Bruton's tyrosine kinase inhibitor tolebrutinib is reportedly the first agent to show benefit in patients with nonrelapsing secondary progressive MS.

A pioneering study presented today at ECTRIMS 2024 has identified critical biomarkers that can predict disability worsening in multiple sclerosis (MS). The breakthrough research has the potential to ...

Microglia are a type of small macrophage-like glial cell in the central nervous system. Microglia can engage in phagocytosis, and are involved in immune responses within, as well as the ...

A pioneering study presented today at ECTRIMS 2024 has identified critical biomarkers that can predict disability worsening ...

A team of researchers has identified critical biomarkers that can predict disability worsening in people with multiple ...

Aug. 23, 2024 — A collaborative investigation among experts in Alzheimer's disease and multiple sclerosis (MS) finds evidence that MS patients are less likely to have amyloid plaques ...

Before Windows, there was MS-DOS—that’s the Microsoft Disk Operating System, if you’re unfamiliar—a text-based, command-line interface operating system that was the way into managing files ...